Cencora, Inc. (NYSE:COR) Position Boosted by First Manhattan CO. LLC.

First Manhattan CO. LLC. grew its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 12.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 265,783 shares of the company's stock after buying an additional 30,031 shares during the quarter. First Manhattan CO. LLC. owned about 0.14% of Cencora worth $59,716,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JFS Wealth Advisors LLC increased its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of Cencora in the fourth quarter worth about $29,000. SBI Securities Co. Ltd. purchased a new stake in shares of Cencora in the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares during the period. Finally, Kentucky Trust Co purchased a new stake in shares of Cencora in the fourth quarter worth about $33,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Down 0.2%

NYSE COR traded down $0.65 on Friday, hitting $283.12. 2,786,039 shares of the stock traded hands, compared to its average volume of 1,526,366. The stock has a 50-day moving average of $276.48 and a 200 day moving average of $253.57. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $309.35. The company has a market capitalization of $54.90 billion, a P/E ratio of 40.27, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the prior year, the firm posted $3.80 earnings per share. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's payout ratio is 25.52%.

Wall Street Analysts Forecast Growth

COR has been the subject of several analyst reports. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Robert W. Baird increased their price target on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday. Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Finally, Morgan Stanley set a $288.00 price target on Cencora in a report on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $301.18.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the sale, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. This represents a 4.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is currently owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.